Stay updated on XmAb®20717 in Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the XmAb®20717 in Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the XmAb®20717 in Metastatic Prostate Cancer Clinical Trial page
- Check6 days agoChange DetectedRevision history updated to include Revision: v3.3.4 and remove Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page history shows a new Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check49 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.2.0 from the Study Record History.SummaryDifference0.1%

- Check63 days agoChange DetectedRemoved the government funding/disclaimer notice at the top of the page; the rest of the content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check77 days agoChange DetectedVisual changes are limited to layout updates (header/footer) with no changes to study data or record history content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check106 days agoChange DetectedMajor update: adds a government funding and operating status notice and marks the page as revision v3.2.0, replacing v3.1.0.SummaryDifference12%

Stay in the know with updates to XmAb®20717 in Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XmAb®20717 in Metastatic Prostate Cancer Clinical Trial page.